Novavax Stock Z Score
NVAX Stock | USD 4.29 0.20 4.89% |
Novavax |
Novavax Company Z Score Analysis
Novavax's Z-Score is a simple linear, multi-factor model that measures the financial health and economic stability of a company. The score is used to predict the probability of a firm going into bankruptcy within next 24 months or two fiscal years from the day stated on the accounting statements used to calculate it. The model uses five fundamental business ratios that are weighted according to algorithm of Professor Edward Altman who developed it in the late 1960s at New York University..
| |||||||
| |||||||
| |||||||
| |||||||
|
To calculate a Z-Score, one would need to know a company's current working capital, its total assets and liabilities, and the amount of its latest earnings as well as earnings before interest and tax. Z-Scores can be used to compare the odds of bankruptcy of companies in a similar line of business or firms operating in the same industry. Companies with Z-Scores above 3.1 are generally considered to be stable and healthy with a low probability of bankruptcy. Scores that fall between 1.8 and 3.1 lie in a so-called 'grey area,' with scores of less than 1 indicating the highest probability of distress. Z Score is a used widely measure by financial auditors, accountants, money managers, loan processors, wealth advisers, and day traders. In the last 25 years, many financial models that utilize z-scores proved it to be successful as a predictor of corporate bankruptcy.
Competition |
Based on the company's disclosures, Novavax has a Z Score of 0.0. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The z score for all United States stocks is 100.0% higher than that of the company.
Did you try this?
Run Stock Screener Now
Stock ScreenerFind equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. |
All Next | Launch Module |
Novavax Fundamentals
Return On Equity | -8.98 | ||||
Return On Asset | -0.17 | ||||
Profit Margin | (0.55) % | ||||
Operating Margin | (0.63) % | ||||
Current Valuation | 284.54 M | ||||
Shares Outstanding | 139.95 M | ||||
Shares Owned By Insiders | 4.99 % | ||||
Shares Owned By Institutions | 57.43 % | ||||
Number Of Shares Shorted | 43.77 M | ||||
Price To Earning | (1.36) X | ||||
Price To Book | 49.52 X | ||||
Price To Sales | 0.61 X | ||||
Revenue | 983.71 M | ||||
Gross Profit | (156.04 M) | ||||
EBITDA | (373.8 M) | ||||
Net Income | (545.06 M) | ||||
Cash And Equivalents | 1.28 B | ||||
Cash Per Share | 16.31 X | ||||
Total Debt | 280.63 M | ||||
Debt To Equity | 8.24 % | ||||
Current Ratio | 1.05 X | ||||
Book Value Per Share | (5.14) X | ||||
Cash Flow From Operations | (717.56 M) | ||||
Short Ratio | 10.22 X | ||||
Earnings Per Share | (5.41) X | ||||
Target Price | 15.4 | ||||
Number Of Employees | 1.54 K | ||||
Beta | 1.6 | ||||
Market Capitalization | 572.41 M | ||||
Total Asset | 1.86 B | ||||
Retained Earnings | (4.82 B) | ||||
Working Capital | (491.25 M) | ||||
Current Asset | 287.26 M | ||||
Current Liabilities | 76.49 M | ||||
Net Asset | 1.86 B |
About Novavax Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Novavax's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Novavax using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Novavax based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Novavax in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Novavax's short interest history, or implied volatility extrapolated from Novavax options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Novavax Piotroski F Score and Novavax Valuation analysis. For more information on how to buy Novavax Stock please use our How to Invest in Novavax guide.Note that the Novavax information on this page should be used as a complementary analysis to other Novavax's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Stock Tickers module to use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites.
Complementary Tools for Novavax Stock analysis
When running Novavax's price analysis, check to measure Novavax's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novavax is operating at the current time. Most of Novavax's value examination focuses on studying past and present price action to predict the probability of Novavax's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novavax's price. Additionally, you may evaluate how the addition of Novavax to your portfolios can decrease your overall portfolio volatility.
Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
Fundamental Analysis View fundamental data based on most recent published financial statements | |
Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
CEOs Directory Screen CEOs from public companies around the world | |
Stocks Directory Find actively traded stocks across global markets | |
Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets |
Is Novavax's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Novavax. If investors know Novavax will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Novavax listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Novavax is measured differently than its book value, which is the value of Novavax that is recorded on the company's balance sheet. Investors also form their own opinion of Novavax's value that differs from its market value or its book value, called intrinsic value, which is Novavax's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Novavax's market value can be influenced by many factors that don't directly affect Novavax's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Novavax's value and its price as these two are different measures arrived at by different means. Investors typically determine if Novavax is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Novavax's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.